In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

DME is a diabetes complication that threatens your the clarity of your vision. But managing blood sugar, blood pressure, and ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

Eyes of patients with pseudophakic cystoid macular edema demonstrated greater retinal nerve fiber layer (RNFL) thickness compared with healthy eyes. The retinal nerve fiber layer (RNFL) was found to ...

Researchers have found in a new study that advanced periodontal inflammation (stage III–IV) may cause degenerative changes in retinal microvasculature and neural tissues. The increasing severity ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...